vs

Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and USA Compression Partners, LP (USAC). Click either name above to swap in a different company.

USA Compression Partners, LP is the larger business by last-quarter revenue ($252.5M vs $168.4M, roughly 1.5× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 2.7%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 4.9%).

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

USA Compression Partners, LP is a US-based provider of natural gas compression services and related infrastructure solutions. It serves clients across the upstream, midstream, and downstream segments of the oil and gas industry, offering custom compression systems, maintenance, and operational support to facilitate efficient natural gas production, processing, and transportation.

ESPR vs USAC — Head-to-Head

Bigger by revenue
USAC
USAC
1.5× larger
USAC
$252.5M
$168.4M
ESPR
Growing faster (revenue YoY)
ESPR
ESPR
+141.0% gap
ESPR
143.7%
2.7%
USAC
Faster 2-yr revenue CAGR
ESPR
ESPR
Annualised
ESPR
10.6%
4.9%
USAC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ESPR
ESPR
USAC
USAC
Revenue
$168.4M
$252.5M
Net Profit
$27.8M
Gross Margin
Operating Margin
50.6%
30.3%
Net Margin
11.0%
Revenue YoY
143.7%
2.7%
Net Profit YoY
9.1%
EPS (diluted)
$0.32

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESPR
ESPR
USAC
USAC
Q4 25
$168.4M
$252.5M
Q3 25
$87.3M
$250.3M
Q2 25
$82.4M
$250.1M
Q1 25
$65.0M
$245.2M
Q4 24
$69.1M
$245.9M
Q3 24
$51.6M
$240.0M
Q2 24
$73.8M
$235.3M
Q1 24
$137.7M
$229.3M
Net Profit
ESPR
ESPR
USAC
USAC
Q4 25
$27.8M
Q3 25
$-31.3M
$34.5M
Q2 25
$-12.7M
$28.6M
Q1 25
$-40.5M
$20.5M
Q4 24
$25.4M
Q3 24
$-29.5M
$19.3M
Q2 24
$-61.9M
$31.2M
Q1 24
$61.0M
$23.6M
Operating Margin
ESPR
ESPR
USAC
USAC
Q4 25
50.6%
30.3%
Q3 25
-11.4%
33.5%
Q2 25
8.6%
30.6%
Q1 25
-34.0%
28.3%
Q4 24
-6.4%
30.3%
Q3 24
-31.0%
31.5%
Q2 24
3.5%
32.9%
Q1 24
52.5%
29.2%
Net Margin
ESPR
ESPR
USAC
USAC
Q4 25
11.0%
Q3 25
-35.9%
13.8%
Q2 25
-15.4%
11.4%
Q1 25
-62.2%
8.4%
Q4 24
10.3%
Q3 24
-57.2%
8.1%
Q2 24
-83.9%
13.3%
Q1 24
44.3%
10.3%
EPS (diluted)
ESPR
ESPR
USAC
USAC
Q4 25
$0.32
Q3 25
$-0.16
Q2 25
$-0.06
Q1 25
$-0.21
Q4 24
$-0.14
Q3 24
$-0.15
Q2 24
$-0.33
Q1 24
$0.34

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESPR
ESPR
USAC
USAC
Cash + ST InvestmentsLiquidity on hand
$167.9M
$8.6M
Total DebtLower is stronger
$2.5B
Stockholders' EquityBook value
$-302.0M
Total Assets
$465.9M
$2.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESPR
ESPR
USAC
USAC
Q4 25
$167.9M
$8.6M
Q3 25
$92.4M
Q2 25
$86.1M
$2.0K
Q1 25
$114.6M
$2.0K
Q4 24
$144.8M
$14.0K
Q3 24
$144.7M
$79.0K
Q2 24
$189.3M
$9.0K
Q1 24
$226.6M
$8.0K
Total Debt
ESPR
ESPR
USAC
USAC
Q4 25
$2.5B
Q3 25
$2.5B
Q2 25
$2.5B
Q1 25
$2.5B
Q4 24
$2.5B
Q3 24
$2.5B
Q2 24
$2.5B
Q1 24
$2.5B
Stockholders' Equity
ESPR
ESPR
USAC
USAC
Q4 25
$-302.0M
Q3 25
$-451.4M
Q2 25
$-433.5M
Q1 25
$-426.2M
Q4 24
$-388.7M
Q3 24
$-370.2M
Q2 24
$-344.2M
Q1 24
$-294.3M
Total Assets
ESPR
ESPR
USAC
USAC
Q4 25
$465.9M
$2.6B
Q3 25
$364.0M
$2.7B
Q2 25
$347.1M
$2.7B
Q1 25
$324.0M
$2.7B
Q4 24
$343.8M
$2.7B
Q3 24
$314.1M
$2.8B
Q2 24
$352.3M
$2.8B
Q1 24
$373.1M
$2.8B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESPR
ESPR
USAC
USAC
Operating Cash FlowLast quarter
$45.2M
$139.5M
Free Cash FlowOCF − Capex
$87.7M
FCF MarginFCF / Revenue
34.8%
Capex IntensityCapex / Revenue
0.0%
20.5%
Cash ConversionOCF / Net Profit
5.02×
TTM Free Cash FlowTrailing 4 quarters
$277.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESPR
ESPR
USAC
USAC
Q4 25
$45.2M
$139.5M
Q3 25
$-4.3M
$75.9M
Q2 25
$-31.4M
$124.2M
Q1 25
$-22.6M
$54.7M
Q4 24
$-35.0M
$130.2M
Q3 24
$-35.3M
$48.5M
Q2 24
$-7.2M
$96.7M
Q1 24
$53.8M
$65.9M
Free Cash Flow
ESPR
ESPR
USAC
USAC
Q4 25
$87.7M
Q3 25
$51.9M
Q2 25
$101.1M
Q1 25
$36.3M
Q4 24
$101.2M
Q3 24
$-35.5M
$19.8M
Q2 24
$-7.3M
$48.2M
Q1 24
$53.8M
$-32.7M
FCF Margin
ESPR
ESPR
USAC
USAC
Q4 25
34.8%
Q3 25
20.7%
Q2 25
40.4%
Q1 25
14.8%
Q4 24
41.1%
Q3 24
-68.7%
8.2%
Q2 24
-9.9%
20.5%
Q1 24
39.0%
-14.3%
Capex Intensity
ESPR
ESPR
USAC
USAC
Q4 25
0.0%
20.5%
Q3 25
0.0%
9.6%
Q2 25
0.0%
9.3%
Q1 25
0.0%
7.5%
Q4 24
0.0%
11.8%
Q3 24
0.3%
12.0%
Q2 24
0.1%
20.6%
Q1 24
0.1%
43.0%
Cash Conversion
ESPR
ESPR
USAC
USAC
Q4 25
5.02×
Q3 25
2.20×
Q2 25
4.35×
Q1 25
2.66×
Q4 24
5.12×
Q3 24
2.51×
Q2 24
3.10×
Q1 24
0.88×
2.80×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESPR
ESPR

Collaboration Revenue$124.7M74%
Products$43.7M26%

USAC
USAC

Revenue From Contract Operations Excluding Revenue From Related Party$231.7M92%
Entities Affiliated With Energy Transfer LP$16.6M7%
Transferred At Point In Time$5.4M2%

Related Comparisons